Firefly Aerospace's successful Nasdaq debut, raising $868M and reaching a valuation close to $10B, reflects strong investor enthusiasm for its space technology.
Lilly's oral weight loss pill trails rivals in efficacy, faces market delay due to tolerability concerns.
Expedia Group reports strong Q2 2025 results, raises full-year guidance amid international gains, sending shares higher.
Firefly Aerospace's successful Nasdaq debut, raising $868M and reaching a valuation close to $10B, reflects strong investor enthusiasm for its space technology.
Lilly's oral weight loss pill trails rivals in efficacy, faces market delay due to tolerability concerns.
Expedia Group reports strong Q2 2025 results, raises full-year guidance amid international gains, sending shares higher.